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Abstract
Objective: Gastrointestinal symptoms are a common feature in children with autism, drawing attention to a potential
association with celiac disease or gluten sensitivity. However, studies to date regarding the immune response to gluten in
autism and its association with celiac disease have been inconsistent. The aim of this study was to assess immune reactivity
to gluten in pediatric patients diagnosed with autism according to strict criteria and to evaluate the potential link between
autism and celiac disease.
Methods: Study participants included children (with or without gastrointestinal symptoms) diagnosed with autism
according to both the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview, Revised (ADI-
R) (n = 37), their unaffected siblings (n = 27), and age-matched healthy controls (n = 76). Serum specimens were tested for
antibodies to native gliadin, deamidated gliadin, and transglutaminase 2 (TG2). Affected children were genotyped for celiac
disease associated HLA-DQ2 and -DQ8 alleles.
Results: Children with autism had significantly higher levels of IgG antibody to gliadin compared with unrelated healthy
controls (p,0.01). The IgG levels were also higher compared to the unaffected siblings, but did not reach statistical
significance. The IgG anti-gliadin antibody response was significantly greater in the autistic children with gastrointestinal
symptoms in comparison to those without them (p,0.01). There was no difference in IgA response to gliadin across groups.
The levels of celiac disease-specific serologic markers, i.e., antibodies to deamidated gliadin and TG2, did not differ between
patients and controls. An association between increased anti-gliadin antibody and presence of HLA-DQ2 and/or -DQ8 was
not observed.
Conclusions: A subset of children with autism displays increased immune reactivity to gluten, the mechanism of which
appears to be distinct from that in celiac disease. The increased anti-gliadin antibody response and its association with GI
symptoms points to a potential mechanism involving immunologic and/or intestinal permeability abnormalities in affected
children.
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Introduction
Glutens are the major storage proteins of wheat and related
cereals, comprising over 70 different molecules in any given wheat
variety [1]. The main classes of gluten include a/b-gliadins, c-
gliadins, v-gliadins, high molecular weight glutenins, and low
molecular weight glutenins [2]. Gluten sensitivity can be defined as
a state of heightened immunologic reaction to gluten proteins,
which may be accompanied by increased levels of antibodies
against them. Heightened immune reactivity to gluten is
recognized and understood best in the context of celiac disease,
an autoimmune disorder primarily targeting the small intestine,
and wheat allergy [3]. The humoral immune response in celiac
disease also includes antibodies to deamidated sequences of gliadin
and to the autoantigen transglutaminase 2 (TG2), which are highly
specific and sensitive serologic markers of the condition [4]. Celiac
disease is also closely linked with genes that code for human
leukocyte antigens (HLA) DQ2 and DQ8 [5].
While the etiology and pathogenesis of autism are poorly
understood, there is evidence that immune system abnormalities
are associated with symptoms in a substantial number of affected
individuals [6]. In addition, several studies have evaluated
gastrointestinal (GI) symptoms and defects in GI barrier function
in patients with autism [7–10]. A possible association between
autism and celiac disease was first discussed over 40 years ago
[11,12]. Although some studies have pointed to higher frequency
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of celiac disease, family history of celiac disease, or elevated
antibody to gliadin among autistic children [13–15], others have
not supported these findings [16–18]. Diets that exclude gluten are
becoming increasingly popular in the autism community, but their
effectiveness has not been proven in controlled and blinded studies
[19]. Despite years of speculation and immense interest by families
of affected children regarding the potential connection between
autism and gluten sensitivity, no well-controlled study has been
performed to determine the levels of immune reactivity to gluten
in patients, to characterize the antigenic specificity of this immune
response, or to assess its pathogenic relevance to autism. In this
study, we examine and compare markers of celiac disease and
gluten sensitivity in cohorts of individuals diagnosed with autism,




The study included 140 children, including 37 with autism, 27
unaffected siblings of similar ages within the same families, and 76
unrelated healthy controls. Serum samples from individuals with
autism and their siblings were acquired from the Autism Genetic
Resource Exchange (AGRE). DNA samples from the 37 children
with autism were also provided by AGRE. Participants in the
AGRE program have been recruited primarily from the north-
eastern and western United States. Affected children met the
diagnostic criteria for autism based on both the Autism Diagnostic
Observation Schedule (ADOS) and the Autism Diagnostic
Interview, Revised (ADI-R). All available serum samples satisfying
the above criteria were included. Information on GI symptoms
was based on parent questionnaires, interviews, and medical
histories. The data collected by AGRE from these evaluations
were retrieved from the online AGRE phenotype database. The
control sera were from healthy children in the United States
(n = 14) and Sweden (n= 62). The healthy controls from U.S.
resided primarily in Connecticut, north New Jersey, and New
York City, and were recruited in a general pediatric clinic at the
Weill Cornell Medical College. The healthy controls from Sweden
were recruited at child health care centres and schools in the Falun
region of central Sweden [20]. Screening questionnaires were used
to evaluate the general health of the U.S. and Swedish controls,
and individuals who reported having a chronic disease were not
included. Serum from a biopsy-proven celiac disease patient,
diagnosed according to previously described criteria [21] at
Columbia University Medical Center, was used as a positive
control for the antibody assays. Written informed consent was
obtained for all study participants from the individual, next of kin,
caretaker, or guardian. The consent procedures were approved by
the Institutional Review Boards of the involved organizations
(AGRE, Columbia University, Weill Cornell Medical College, and
Uppsala University). Complete documentation of consent is
maintained at the respective organizations. This specific study
was approved by the Institutional Review Board of Columbia
University Medical Center. Specimens were kept at 280uC to
maintain stability.
Gliadin
The antigen mixture used for the anti-gliadin antibody assays
was the Prolamine Working Group (PWG) reference gliadin,
which was extracted from a combination of 28 different wheat
varieties, as previously described [22]. The protein profile of the
PWG gliadin extract was assessed by SDS-polyacrylamide gel
electrophoresis, using 10% NuPAGE Bis-Tris precast gels and 3-
(N-morpholino)propanesulfonic acid (MOPS) buffer (Life Tech-
nologies, Carlsbad, Calif.).
Anti-gliadin Antibodies
Serum IgG and IgA antibodies to gliadin were measured
separately by enzyme-linked immunosorbent assay (ELISA) as
previously described [23,24], with some modifications. A 2 mg/
mL stock solution of the PWG gliadin was prepared in 60%
ethanol. 96-well Maxisorp round-bottom polystyrene plates (Nunc,
Roskilde, Denmark) were coated with 50 mL/well of a 0.01 mg/
mL solution of PWG gliadin in 0.1 M carbonate buffer (pH 9.6) or
were left uncoated to serve as control wells. After incubation at
37uC for 1 h, all wells were washed and blocked by incubation
with 1% bovine serum albumin (BSA) in phosphate buffered saline
containing 0.05% Tween-20 (PBST) for 1.5 h at room temper-
ature. Serum samples were diluted at 1:800 for IgG measurement
and at 1:200 for IgA measurement, added at 50 mL/well in
duplicates, and incubated for 1 h. Each plate contained a positive
control sample from a patient with biopsy-proven celiac disease
and elevated IgG and IgA antibodies to gliadin. After washing the
wells, they were incubated with HRP-conjugated anti-human IgG
(GE Healthcare, Piscataway, N.J.) or IgA (MP Biomedicals, Santa
Ana, Calif.) secondary antibodies for 50 min. The plates were
washed and 50 mL of developing solution, comprising of 27 mM
citric acid, 50 mM Na2HPO4, 5.5 mM o-phenylenediamine, and
0.01% H2O2 (pH 5), was added to each well. After incubating the
plates at room temperature for 20 min, absorbance was measured
at 450 nm. All serum samples were tested in duplicate. Absor-
bance values were corrected for non-specific binding by subtrac-
tion of the mean absorbance of the associated BSA-coated wells.
The corrected values were first normalized according to the mean
value of the positive control duplicate on each plate. The mean
antibody level for the unrelated healthy control cohort was then set
as 1.0 AU and all other results were normalized accordingly.
Anti-transglutaminase 2 (TG2) Antibodies
IgA antibody to recombinant human TG2 was measured in sera
using an ELISA kit, according to the manufacturer’s protocol
(Euroimmun, Lubeck, Germany).
Anti-deamidated Gliadin Antibodies
Sera were tested separately for IgG and IgA antibodies to a
previously described glutamine-glutamate substituted trimer of a
fusion peptide containing the sequences PLQPEQPFP and
PEQLPQFEE [25] by ELISA, according to the manufacturer’s
protocols (Euroimmun).
HLA Typing
High resolution HLA genotyping was performed by multiplex
polymerase chain reaction (PCR) with biotinylated primers,
followed by reverse hybridization of the PCR products to line
arrays of sequence-specific DQA1 and DQB1 oligonucleotide
probes, using INNO-LiPA HLA-DQ kits, according to the
manufacturer’s instructions (Innogenetics, Gent, Belgium). Pres-
ence or absence of celiac disease-associated DQA1*0501/0505-
DQB1*0201/0202 (DQ2) and DQA1*03-DQB1*0302 (DQ8)
genes was determined.
Data Analysis
Differences between groups were analyzed by the two-tailed
Student’s t test, Welch’s t test, Mann-Whitney U test, or one-way
analysis of variance (ANOVA) with post-hoc Dunn test (contin-
uous data), and the Fisher’s exact test (nominal data). Adjustment
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for covariate effect (age, gender, and race) was carried out by
analysis of covariance (ANCOVA), using the general linear model.
Logistic regression was used to calculate the odds ratios associated
with increased antibodies in individuals with autism. For these
analyses, increased levels of anti-gliadin antibody were defined as
values at the 95th percentile or higher in the unrelated healthy
control group. For IgA anti-TG2 antibody and IgG/IgA anti-
deamidated gliadin antibodies, cutoffs for positivity were assigned
by the manufacturer. Differences with p values of ,0.05 were
considered to be statistically significant. Statistical analyses were
performed with Prism 5 (GraphPad, San Diego, Calif.) and
Minitab 16 (Minitab, State College, Pa.).
Results
Patients and Controls
The demographic and clinical characteristics of the patients
with autism, their unaffected siblings, and unrelated healthy
controls are shown in Table 1. The patient cohort included four
individuals on gluten-free diet. Because the effect of gluten-free
diet on antibody levels in autism is not known, these patients were
not excluded from the study.
Gliadin
The gel electrophoresis profile for the PWG gliadin used in anti-
gliadin antibody assays indicated the presence of all main types of
gliadin proteins, a/b, c, and v. The mixture also contained high
and low molecular weight glutenin subunits (Fig. 1).
Antibody Levels
Mean levels of IgG and IgA class antibodies to gliadin in patient
and control groups are presented in Fig. 2. Children with autism
exhibited significantly elevated levels of IgG antibody to gliadin
when compared with unrelated healthy controls or when
compared with the combination of unaffected siblings and
unrelated healthy controls (p,0.01). The difference remained
significant after adjusting for the covariates of age, gender, and
race (p,0.01). The anti-gliadin IgG differences between the
children with autism and their unaffected siblings, and between
the siblings and unrelated healthy controls, did not reach statistical
significance. Based on the stated cutoff for positivity (95th
percentile of the healthy control group), 8/33 (24.2%) of the
children with autism, excluding those who reported being on
gluten-free diet, 8/37 (21.6%) of all autistic children, including
those on gluten-free diet, 2/27 (7.4%) of unaffected siblings, and
4/76 (5.3%) of unrelated healthy children were positive for IgG
anti-gliadin antibody, indicating a significantly higher frequency in
those with autism compared to unrelated healthy controls
(p,0.01). Children with autism had increased odds of having
elevated IgG antibody to gliadin in comparison to healthy controls
(odds ratio: 4.97; 95% confidence interval: 1.39–17.8). The
differences in levels of IgA antibody to gliadin among the three
groups were not significant.
All patients and controls were also tested for the currently
recommended full panel of the most sensitive and specific serologic
markers of celiac disease, including IgA antibody to TG2, IgG
antibody to deamidated gliadin, and IgA antibody to deamidated
gliadin. None of the individuals in any group were positive for IgA
antibody to TG2. Two of 37 autistic children, 3 of 27 unaffected
siblings, and none of 76 unrelated healthy controls had values
above the manufacturer’s assigned cutoff for IgG antibody to
deamidated gliadin. Similarly, none of 37 autistic children, 1 of 27
unaffected siblings, and 1 of 76 unrelated healthy controls were
positive for IgA antibody to deamidated gliadin.
All four individuals who were on gluten-free diet were negative
for anti-gliadin, anti-deamidated gliadin, and anti-TG2 antibodies.
HLA Typing
In the group of children with autism, 18/37 (48.6%) were
positive for HLA-DQ2 and/or -DQ8 (6 DQ2, 12 DQ8). There
was no clear association between antibody to gliadin and the
presence of celiac disease-associated HLA-DQ2/DQ8 in patients
with autism: 3/8 (37.5%) of the anti-gliadin antibody-positive
individuals with autism displayed HLA-DQ2 and/or DQ8 (2
Table 1. Demographic characteristics of study cohorts.
Subject group Number of subjects Mean age– years 6 SD Male sex– no. (%) White race no. (%)
Autism 37 7.862.9 29 (78) 33 (89)
With GI symptoms 19 7.162.3 13 (68) 15 (79)
Without GI symptoms 8 7.162.3 6 (75) 8 (100)
Unaffected sibling 27 8.162.9 18 (67) 25 (93)
Unrelated healthy 76 8.863.7 59 (77) 70 (92)
doi:10.1371/journal.pone.0066155.t001
Figure 1. Gel electrophoresis profile of the PWG gliadin
preparation used for the anti-gliadin antibody assays. A) 5 mg
of protein loaded; B) 10 mg of protein loaded.
doi:10.1371/journal.pone.0066155.g001
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DQ2, 1 DQ8), while 15/29 (51.7%) of those below the cutoff for
antibody positivity had DQ2 and/or DQ8. Neither of the two
patients with autism who were positive for IgG anti-deamidated
gliadin antibody had DQ2 or DQ8. About 95% or more of celiac
disease patients carry HLA-DQ2 and/or -DQ8, compared to an
estimated 40% of the U.S. general population [26].
GI Symptoms
Medical histories were available for 27 of the 37 children with
autism. 19/27 (70.3%) reported persistent GI symptoms, including
10 with chronic loose stools or diarrhea, 2 with gastroesophageal
reflux, 3 with frequent stools, 3 with constipation, and 1 with non-
specified GI symptoms. Affected patients with GI symptoms were
found to have significantly higher levels of IgG antibody to gliadin
when compared to patients without GI symptoms (p,0.01)
(Fig. 3A). This difference remained significant after adjusting for
the covariates of age, gender, and race (p,0.01). Information on
GI symptoms was available for 5 of the 8 children whose anti-
gliadin antibody levels were determined to be above the cutoff.
They included 3 with chronic loose stools or diarrhea, 1 with
frequent stools, and 1 with constipation.
There was no significant difference in the levels of IgA antibody
to gliadin (Fig. 3A), IgG and IgA antibodies to deamidated gliadin
(Fig. 3B), and IgA antibody to TG2 (Fig. 3C) between patients
with GI complaints and those without. One autism patient with GI
symptoms was positive for IgG antibody to deamidated gliadin,
while the remaining patients in both groups were negative for all
other markers.
Discussion
The aim of this study was to carry out a comprehensive analysis
of markers of celiac disease and gluten sensitivity in a group of
children with autism who had been diagnosed according to strict
criteria and defined instruments. Our data indicate that children
with autism have higher levels of IgG antibody to gliadin
compared to healthy controls. In addition, among patients with
autism, the antibody response to gliadin was greater in those with
GI symptoms. However, in contrast to patients with celiac disease,
no association was observed between the elevated anti-gliadin
antibody level and the presence of highly specific serologic markers
of celiac disease or HLA-DQ2/DQ8. The findings indicate that
the observed anti-gliadin immune response in patients with autism
is likely to involve a mechanism that is distinct from celiac disease,
without the requirement for TG2 activity or antigen presentation
through DQ2/DQ8 MHC molecules [27].
The data from this study should be interpreted with caution.
Most importantly, the observed increased IgG antibody response
to gliadin does not necessarily indicate sensitivity to gluten or any
pathogenic role for antibodies to gliadin in the context of autism.
In addition, the results do not rule out the possibility of moderately
increased prevalence of celiac disease among children with autism,
especially as duodenal biopsy, the gold standard for definitive
diagnosis of celiac disease, was not performed. However,
considering the excellent sensitivity and specificity of anti-TG2
and (and to a lesser extent anti-deamidated gliadin) antibodies, as
well as the high negative predictive value of HLA-DQ2/DQ8
markers for celiac disease, it can be concluded with high certainty
that the overwhelming majority of autism patients with elevated
antibody to gliadin do not have celiac disease. If future studies
prove the existence of sensitivity to gluten in a subset of patients
with autism, the gluten-associated symptoms in such individuals
may fall within the spectrum of ‘‘non-celiac gluten sensitivity’’
[28].
Compared to previous reports examining the link between
celiac disease/gluten sensitivity and autism, this study is unique in
several ways. First, a shortcoming in earlier studies has been the
lack or incompleteness of suitable age-matched healthy control
groups necessary for this type of analysis. In this work, the
antibody levels in children with autism were compared to two
separate pediatric control groups: unaffected siblings of the same
patients, as well as a larger cohort of unrelated healthy children.
Second, previous reports have used specimens from more
heterogeneous groups of patients generally recruited at local
hospitals or clinics, and while most report the use of DSM
diagnostic criteria, it is unclear which test(s) informed the final
diagnosis of autism. In contrast, the samples in this study were
acquired from a well-recognized repository of biomaterials
(AGRE), which is managed by the world’s largest autism advocacy
organization and has been utilized in various past research
projects. The associated AGRE database includes information
about family pedigree, scores from various tests and question-
naires, and medical histories for many of the patients for which
biospecimens are available. Patients in this study were selected
only if they were identified as having autism according to two
separate instruments, ADOS and ADI-R, thus greatly increasing
the likelihood of accurate diagnosis.
A limitation of this study is that we could not control for
geographical distribution, socioeconomic status, or diet of the
research participants. These factors may contribute to levels of
antibodies against dietary and other antigens in patients and
controls. In addition, information on GI symptoms was available
only for some patients and none of the controls. Access to such
data would have strengthened the study’s finding regarding the
association between GI symptoms and anti-gliadin antibody levels.
As such, the conclusions of this study should be considered
preliminary, requiring further confirmation in larger and better-
characterized cohorts of patients and controls.
Figure 2. Comparison of levels of IgG and IgA antibody to
gliadin in children with autism, their unaffected siblings, and
unrelated healthy controls. Boxed segments represent the middle
50% of the data. Whiskers indicate the range of data. Large horizontal
bars indicate mean value of the data. ** = p,0.01.
doi:10.1371/journal.pone.0066155.g002
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We can consider some possibilities to explain the higher anti-
gliadin antibody levels found in the cohort of children with autism.
Previously, associationsbetweenautismand increasedGI symptoms,
as well as impaired intestinal permeability, have been reported
[9,10,29]. Increased intestinalpermeability resulting fromdamage to
the intestinal epithelial barrier in those with autism may be
responsible for increased exposure of the immune system to partially
digested gluten fragments, resulting in the detected increase in
antibody response. The observation here that anti-gliadin antibody
reactivity iselevated inpatientswithGIsymptoms lendssomesupport
for this idea. At the same time, the fact that the higher anti-gliadin
antibodies inautisticchildrenwere limited to theIgGisotype,without
a concomitant rise in IgA, may imply a non-mucosal and/or gluten-
independent origin for the observed antibody reactivity. One
possibility is that the IgG-specific antibody response in children with
autismwould have been triggered by ingested gluten at somepoint in
thepast, butno longerdependentoncontinuousmucosal exposure to
the proteins. Alternatively, the detected anti-gliadin antibodies may
be unrelated to gluten as the immunogen. Various immune
abnormalities havebeendemonstrated inautistic children, including
increased antibody reactivity to autoantigens [30–32]. It is conceiv-
able that certain autism-associated autoantibodies, the exact targets
of which are yet to be identified, would cross-react with one or more
gluten proteins and contribute to the detected difference in anti-
gliadin antibody level between patients and controls. Circulation
levelsof suchantigen-independentorglutencross-reactiveantibodies
would not be expected to respond to dietary gluten restriction.
Results of this study are intriguing in the context of disease
pathophysiology and biomarker identification. The observed
increase in antibody reactivity to gliadin in over one fifth of the
autism cohort points to potential shared genetic and/or environ-
mental associations in a sizable subset of patients. As such, the
generated data provide an impetus to further examine the affected
patient subset for additional immunologic and genomic clues. It is
possible that, in a subset of children with autism, the condition is
associated with antibody reactivity to a unique set of gluten proteins
that would be significantly different from the pattern of anti-gliadin
antibody response in celiac disease and other conditions. This
specific pattern of antibody reactivity may be useful as a source of
biomarkers. A unique antibody response to particular gluten
molecules could also be associated with specific HLA genes in that
disease subset.
In conclusion, the increased anti-gliadin antibody response in
autism and its association with GI symptoms points to a potential
mechanism involving immunologic and/or intestinal permeability
abnormalities in a subset of patients. The observed antibody
reactivity to gliadin in most children with autism appears to be
unrelated to celiac disease. Therefore, the heightened immune
response to gluten in autism deserves further attention and research
in determining its utility as a source of biomarkers and clues
regarding disease pathophysiology. Better understanding of this
immune response may offer novel markers for the identification of
subsets of patients who would be responsive to specific treatment
strategies.
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